Callender VD, et al. - Researchers explored the safety and effectiveness of crisaborole ointment, 2%, depending on race [Asian/native Hawaiian/other Pacific Islander, black/African American, and other/American Indian/Alaskan native] and ethnicity [Hispanic/Latino or not Hispanic/Latino] for the treatment of mild-to-moderate atopic dermatitis in patients aged ≥ 2 years. In the pivotal trials, the frequency of crisaborole-related adverse events was 7.1–8.5%. Regardless of race or ethnicity, in patients aged ≥ 2 years with mild-to-moderate atopic dermatitis, crisaborole improved global disease severity. Crisaborole has proved efficacy in treating mild to moderate atopic dermatitis across races and ethnicities, with a low frequency of adverse events associated with therapy.